Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,600 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $19.99, for a total value of $171,914.00. Following the sale, the chief executive officer now directly owns 743,675 shares in the company, valued at approximately $14,866,063.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Atara Biotherapeutics Inc (ATRA) opened at $28.25 on Friday. Atara Biotherapeutics Inc has a twelve month low of $11.80 and a twelve month high of $30.40.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). research analysts forecast that Atara Biotherapeutics Inc will post -4 EPS for the current fiscal year.

A number of brokerages recently issued reports on ATRA. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Goldman Sachs Group reissued a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Finally, Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target on the stock in a research report on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Atara Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $26.00.

Hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. boosted its holdings in shares of Atara Biotherapeutics by 16.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock valued at $1,302,000 after purchasing an additional 13,394 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at $581,000. Vanguard Group Inc. boosted its holdings in shares of Atara Biotherapeutics by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after purchasing an additional 13,952 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at $429,000. Finally, Neuberger Berman Group LLC boosted its holdings in shares of Atara Biotherapeutics by 15.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after purchasing an additional 147,061 shares in the last quarter. 85.61% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Atara Biotherapeutics Inc (ATRA) CEO Sells $171,914.00 in Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/14/atara-biotherapeutics-inc-atra-ceo-sells-171914-00-in-stock.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related stocks with our FREE daily email newsletter.